True North Therapeutics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- April 07, 2015
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $35,000,000
Company Info
- Founders
- Nancy Stagliano
- Company Description
- True North Therapeutics is a biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company's lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway.
- Market
- Rare diseases
- Location
- South San Francisco, California, USA
- Coinvestors
- Baxter Ventures, MPM Capital, OrbiMed Advisors, SR One